UNSPSC 51391749: Eformoterol or formoterol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ZZ84GCW8B. European Medicines Agency schedules Formoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07788MIG. Formoterol generally arises in the molecular formula C19H24N2O4.

The term FORMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) FORMOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Eformoterol or formoterol bears US NLM identifiers UMLS ID C0060657 and NCI Concept Code C65754. SMILES: OC(CNC(CC1CCC(OC)CC1)C)C1CC(NC=O)C(O)CC1.

UNSPSC 51391749 Eformoterol or formoterol, a Commodity code, shows minimal recent activity in state and local procurement that aligns with the code's pharmaceutical scope. The most recent opportunities tagged to this code are not eformoterol or formoterol purchases. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking naloxone and drug deactivation systems—a distinct pharmaceutical product unrelated to eformoterol, which is a long-acting beta-agonist for asthma and COPD management. Similarly, the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs, a pharmacy-benefit-program mechanism rather than procurement of a specific pharmaceutical product. Neither opportunity reflects actual state or local demand for eformoterol or formoterol products.

The code appears dormant or mislabeled in current state and local procurement databases. Without recent opportunities that actually solicit eformoterol or formoterol, the geographic spread, issuing-body patterns, and representative work cannot be characterized from active solicitations. Business development professionals should verify whether state and local health agencies, Medicaid programs, or public health departments are acquiring eformoterol through cooperative purchasing vehicles, GPO contracts, or pharmaceutical distribution channels not yet visible in the public RFP/RFQ/IFB/ITB pipeline, or whether this code is simply not in active use in state and local procurement at this time.